07:30 Registration & Breakfast

08:10 Welcome Speech by Leonard Sachs

| 08:20 | Pharma BDL and M&A Panel - Ballroom AB Co-Chaired by: Anne Altmeyer, VP Business Development Negotiations, Baxalta, Inc. Mike Rice, Senior Consultant, Defined Health Panellists: Birgit Schoeberl, Head of Discovery Division, Merrimack Pharmaceuticals, Inc. Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development, EMD Serono Henry Gosebruch, Executive Vice President and Chief Strategy Officer, AbbVie, Inc. Ji Li, Executive Vice President, Global Head of Business Development, BeiGene, Ltd. Mohamed Ragab, VP, Head Oncology S &E, Business Development, Bristol-Myers Squibb Peter Sandor, Vice President, Oncology Therapeutic Area Head for Marketing Strategy, Astellas Pharma US, Inc. | | | | |
|--|--|----------------|---|--|--|
| 09:10 | "Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and prospects for Cures" James Allison, Chairman, Department of Immunology, Director, Immunology Platform, MD Anderson Cancer Center | | | | |
| 09:40 | "From the clinic to the lab: Investigating immune responses to immune checkpoint therapies" Padmanee Sharma, Scientific Director, Immunotherapy Platform, Professor, Department of Genitourinary Medical Oncology, Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center | | | | |
| 10:10 Coffee Break | | | | | |
| 10:20 | IO Prime and Enhance Strategies Panel - Ballroom AB Co-Chaired by: James Mulé, Associate Center Director for Translational Research, H. Lee Moffitt Cancer Center & Research Institute Paul Rennert, Founder & Principal, SugarCone Biotech LLC, President and CSO, Aleta Biotherapeutics Panellists: Barry Labinger, CEO, Biothera Pharmaceuticals, Inc. Bernard Fox, President & CEO, UbiVac Frank Jones, Chairman and Chief Executive Officer, Etubics Corporation Mark Schwartz, President & CEO, Galena Biopharma, Inc. | | Presenting Companies Track A - Ballroom C Moderated by: Robin Davison Aethlon Medical, Inc [NASDAQ : AEMD] BerGenBio AS | | |
| 11:00 | IO Direct Therapeutic Strategies Panel - Ballroom AB Co-Chaired by: James Mulé, Associate Center Director for Translational Research, H. Lee Moffitt Cancer Center & Research Institute Paul Rennert, Founder & Principal, SugarCone Biotech LLC, President and CSO, Aleta Biotherapeutics Panelists: Francis Kern, Senior Director, External Scientific Affairs, Daiichi Sankyo, Inc. John Haurum, CEO, F-star Biotechnology Ltd. Juergen Gamer, VP Business Development, APOGENIX AG Shaun McNulty, Chief Scientific Officer, Biosceptre International Ltd. | 11:20 11:30 | Biosceptre International Ltd. JW Pharmaceutical Corporation [KRX : 001060] Charité – Universitätsmedizin Berlin Immunicum AB - [SS : IMMU] | | |
| Presenting Companies Track B - Ballroom AB Moderated by: Mike Rice | | | Immune Dharmacouticals Inc. [NASDAQ+IMNID] | | |
| 11:40 | Advaxis, Inc [NASDAQ : ADXS] | 12:00 | Immune Pharmaceuticals, Inc [NASDAQ : IMNP] | | |
| 12:00 | Merrimack Pharmaceuticals, Inc [NASDAQ : MACK] Nanobiotix SA - [EPA : NANO] | 12:20 | UbiVac | | |
| | OSE Immunotherapeutics - [FP : OSE] | 12:40 | Galena Biopharma, Inc. [NASDAQ : GALE] | | |
| 13:00 | Networking Lunch | | | | |

| 13:50 | New Wave Technologies and Companies Panel - Ballroom AB Chaired by: Howard Fingert, Senior Medical Director, Internal and External Innovation for Oncology, Takeda Pharmaceuticals, Inc. Panellists: Bard Geesaman, Managing Director, MPM Capital Deborah Morosini, VP Patient Engagement & Clinical Trials, LOXO Oncology, Inc. Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center Gary Sclar, Chief Research Business Development Officer, Dana-Farber Cancer Institute Kuldeep Neote, Senior Director, New Venture and Scout, J&J Innovation Louise Perkins, Chief Scientific Officer, Melanoma Research Alliance | Presenting Companies Track C - Ballroom C Moderated by: Patrick Frankham | | | |
|--|--|--|---|--|--|
| | | 13:50 | MaxCyte, Inc [LON : MXCT] | | |
| | | 14:10 | APOGENIX AG | | |
| 14:30 | "Driving Advancement in Cancer Immunotherapy" Sophie Kornowski-Bonnet, Head of Roche Partnering, F. Hoffmann-La Roche AG | 14:30 | Biothera Pharmaceuticals, Inc. | | |
| 14:50 | "CAR and TCR-engineered T-cells for the Treatment of Hematologic Malignancies and Solid Tumors" Jeff Wiezorek, SVP, Clinical Development, Kite Pharma, Inc. | | | | |
| | Advances in Cell & Gene Therapies Panel - Ballroom AB Co-Chaired by: | 14:50 | Etubics Corporation | | |
| 15:10 | Boris Peaker, Managing Director, Biotechnology Equity research, Cowen Group, LLC Gregory Frost, Managing Director, F1 BioVentures <i>Panellists:</i> Aaron Foster, Senior Director, R&D, Bellicum Pharmaceuticals, Inc. Axel Hoos, SVP, TA Head Oncology R&D, and Head, Immuno-Oncology, GlaxoSmithKline Plc Francois Lebel, EVP, Research and Development, Chief Medical Officer, ZIOPHARM Oncology, Inc. Helen Tayton-Martin, Chief Operating Officer, Adaptimmune, LLC Madhusudan Peshwa, CSO and Executive Vice President of Cellular Therapies, MaxCyte, Inc. | 15:10 | F-star Biotechnology Ltd. | | |
| | | 15:30 | OncoSec Medical, Inc [NASDAQ : ONCS] | | |
| | Machastical Meshwa, CSO and Executive Vice Hesident of Central Metaples, MaxCyte, Mc. Mark Frohlich, EVP Portfolio Strategy, Juno Therapeutics, Inc. Peter Emtage, Senior Vice President Research and Translational Medicine, Cell Design Labs Robert Petit, Executive Vice President and Chief Scientific Officer, Advaxis, Inc. | | | | |
| 16:10 Coffee Break | | | | | |
| Presenting Companies Track D - Ballroom AB Moderated by: Mike Rice | | | Presenting Companies Track E - Ballroom C Moderated by: Leonard Sachs | | |
| 16:20 | Mirna Therapeutics, Inc [NASDAQ : MIRN] | 16:20 | Ex Scientia Ltd. | | |
| | | 16:30 | Memgen, LLC | | |
| 16:40 | Curis, Inc [NASDAQ : CRIS] | 16:40 | Oncology Venture | | |
| 17:00 | KOL & Investors Panel - Ballroom AB Chaired by: Biren Amin, Managing Director, Jefferies, LLC Panellists: Brad Loncar, Chief Executive Officer, Loncar Investment, LLC Joseph Sum, Analyst, Director of Research, EcoR1 Capital, LLC Lee Greenberger, CSO, The Leukemia & Lymphoma Society Mani Mohindru, Chief Strategy Officer, Curis, Inc. Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, AbbVie, Inc. Rena Conti, Assistant Professor Hematology/Oncology, The University of Chicago Department of Pediatrics Thilo Schroeder, Partner, Nextech Invest Ltd. | | | | |
| 18:00 Networking Reception | | | | | |
| | | | | | |

19:00 End of the 2nd IOBDLI Forum

Silver Sponsor:

Supported by:

Roche

FREEMIND

Non-Dilutive Funding Specialists

BIO DEUTSCHLAND

INSTINCTIF

PARTNERS =

nologie-Industrie-Organisation Deutschland e.V.



BIOTECH GATE

-



Citigate Dewe Rogerson



TIBEREND STRATEGIC ADVISORS, INC.